Jove
Visualize
Contact Us
  1. Home
  3. Using Active Surveillance For Gleason 7 (3+4) Prostate Cancer: A Narrative Review.
  1. Home
  3. Using Active Surveillance For Gleason 7 (3+4) Prostate Cancer: A Narrative Review.

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

205

Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.

Rui Bernardino1,2, Rashid K Sayyid1, Ricardo Leão3

  • 1Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|February 21, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Active surveillance (AS) is expanding to include more prostate cancer (PCa) patients, even those with small-volume Gleason grade group 2 disease. Careful patient selection and monitoring are key to safely managing low intermediate-risk PCa with AS.

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Related Experiment Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

205
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Area of Science:

  • Urology
  • Oncology
  • Medical Surveillance

Background:

  • Growing interest in active surveillance (AS) for prostate cancer (PCa).
  • Expanding AS criteria to include patients beyond traditional low-risk profiles, such as small-volume Gleason grade group 2 disease.
  • Challenges exist in identifying patients with low intermediate-risk PCa who can safely undergo AS without disease progression.

Purpose of the Study:

  • To review the evolving trend of AS in men with low intermediate-risk PCa.
  • To examine strategies for minimizing disease progression in this cohort.
  • To address patient selection, follow-up schedules, and intervention indicators for AS.

Main Methods:

  • Literature review focusing on active surveillance in prostate cancer.
  • Analysis of current trends and challenges in managing low intermediate-risk PCa.
  • Examination of patient selection criteria, follow-up protocols, and intervention triggers.

Main Results:

  • Active surveillance is increasingly considered for a broader range of prostate cancer patients.
  • Identifying suitable candidates for AS in the low intermediate-risk group requires careful evaluation.
  • Strategies to mitigate disease progression and appropriate monitoring are crucial for successful AS.

Conclusions:

  • Active surveillance is a viable option for select men with low intermediate-risk prostate cancer.
  • Refined patient selection and vigilant monitoring are essential for safe and effective AS.
  • Further research is needed to optimize AS protocols for this expanding patient group.